Alivus Life Sciences Limited Stock Price Today (NSE: ALIVUS)
Fundamental Score
Alivus Life Sciences Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Alivus Life Sciences Limited share price today is ₹1374.20, down 1.87% on NSE/BSE as of 22 September 2026. Alivus Life Sciences Limited (ALIVUS) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹16.87K (Cr). The 52-week high for ALIVUS share price is ₹1493.80 and the 52-week low is ₹819.00. At a P/E ratio of 27.98x, ALIVUS is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 18.36% and a debt-to-equity ratio of 0.00.
Alivus Life Sciences Limited Share Price Chart — NSE/BSE Historical Performance
Alivus Life Sciences Limited share price chart: 1.86% return over the past month. 52-week high ₹1493.80, 52-week low ₹819.00.
Alivus Life Sciences Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1439.00 | ₹1446.00 | ₹1390.20 | ₹1400.40 | 2.56L (Cr) | |
| ₹1395.10 | ₹1443.00 | ₹1387.00 | ₹1430.80 | 3.04L (Cr) | |
| ₹1372.80 | ₹1397.90 | ₹1361.10 | ₹1387.80 | 72.11K (Cr) | |
| ₹1350.00 | ₹1390.90 | ₹1317.60 | ₹1370.60 | 1.53L (Cr) | |
| ₹1386.80 | ₹1401.70 | ₹1344.50 | ₹1347.80 | 79.33K (Cr) | |
| ₹1385.00 | ₹1398.10 | ₹1376.10 | ₹1386.80 | 74.37K (Cr) | |
| ₹1407.20 | ₹1414.30 | ₹1381.50 | ₹1390.20 | 72.28K (Cr) | |
| ₹1370.00 | ₹1436.40 | ₹1370.00 | ₹1400.10 | 1.93L (Cr) | |
| ₹1390.70 | ₹1399.80 | ₹1364.60 | ₹1372.00 | 1.06L (Cr) | |
| ₹1377.20 | ₹1419.70 | ₹1361.00 | ₹1388.90 | 1.29L (Cr) |
Alivus Life Sciences Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1414.00 | ₹1470.10 | ₹1317.60 | ₹1400.40 | -0.96% | |
| ₹1182.80 | ₹1493.80 | ₹1172.90 | ₹1405.70 | +18.85% | |
| ₹1159.90 | ₹1193.90 | ₹1086.10 | ₹1160.00 | +0.01% | |
| ₹1060.70 | ₹1176.90 | ₹996.40 | ₹1156.50 | +9.03% | |
| ₹1040.00 | ₹1148.40 | ₹1022.10 | ₹1055.50 | +1.49% | |
| ₹994.00 | ₹1096.00 | ₹957.00 | ₹1038.15 | +4.44% | |
| ₹886.30 | ₹1025.00 | ₹851.15 | ₹972.70 | +9.75% | |
| ₹915.10 | ₹980.00 | ₹878.40 | ₹911.80 | -0.36% | |
| ₹916.60 | ₹966.95 | ₹819.00 | ₹961.05 | +4.85% | |
| ₹898.50 | ₹922.00 | ₹847.20 | ₹916.60 | +2.01% | |
| ₹911.55 | ₹950.00 | ₹877.10 | ₹898.50 | -1.43% | |
| ₹912.80 | ₹956.00 | ₹901.50 | ₹904.45 | -0.91% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Alivus Life Sciences Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Alivus Life Sciences Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ALIVUS across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (18.36%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (23.59%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (30.58%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (31.71%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (140.86x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 5.21)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹1376.86 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (74.91%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
High Price-to-Book Ratio (5.06x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Weak Earnings Growth (-33.26% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Alivus Life Sciences Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Alivus Life Sciences Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Alivus Life Sciences LimitedAlivus Life Sci...Selected✓ ALIVUS • 543322 | 58.6/100 | ₹1374.20₹1374 | ₹16866.93₹16866.93 | 27.98Average 28.0 Average | 18.36%Good 18.36% Good | 23.59%Excellent 23.59% Excellent | 0.00Excellent 0.0 Excellent | 10.65%Good 10.65% Good | 6.24%Good 6.24% Good | 0.43% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Alivus Life Sciences Limited PE Ratio History
Historical price-to-earnings ratio for ALIVUS — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹39.52 | ₹916.60 | 23.2x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Alivus Life Sciences Limited Dividend History
Annual cash dividends paid by ALIVUS — dividend yield 0.43%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2024 | ₹275.69 Cr |
| FY 2023 | ₹385.92 Cr |
| FY 2022 | ₹128.65 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Alivus Life Sciences Limited Quarterly Performance
Latest quarterly metrics for ALIVUS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
6.41%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
31.71%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
6.24%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
10.65%
Compounded annual net profit growth over 5 years
Alivus Life Sciences Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ALIVUS — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Alivus Life Sciences Limited Financial Statements
Annual income statement, balance sheet and cash flow for Alivus Life Sciences Limited (ALIVUS) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Alivus Life Sciences Limited
About ALIVUS (Alivus Life Sciences Limited)
Alivus Life Sciences Limited is a global biopharmaceutical company dedicated to pioneering innovative solutions across a wide spectrum of therapeutic areas. With a robust research ...and development pipeline, Alivus focuses on the discovery, development, and commercialization of novel pharmaceutical products that address unmet medical needs. The company leverages cutting-edge technologies and a collaborative approach to accelerate the development of life-changing therapies for patients worldwide. Alivus Life Sciences is committed to maintaining the highest standards of quality and safety in all aspects of its operations, from research and development to manufacturing and distribution. Alivus Life Sciences Limited harnesses a diverse portfolio of advanced pharmaceutical ingredients, targeting prevalent and debilitating conditions. Specializing in creating intricate molecular compounds, Alivus caters to therapeutic areas such as oncology, neurology, and endocrinology. It offers an extensive range of pharmaceutical products, from innovative small molecules to complex biologics, designed to improve patient outcomes and enhance the quality of life. The company invests heavily in state-of-the-art manufacturing facilities, adhering to rigorous international regulatory standards, ensuring the consistent production of high-quality and safe pharmaceuticals. Alivus Life Sciences Limited operates with a global reach, providing healthcare solutions to diverse markets across continents. Its strategic partnerships and distribution networks enable the company to deliver its products to patients in need. By focusing on precision medicine and personalized therapies, Alivus is shaping the future of healthcare and empowering individuals to live healthier, more fulfilling lives. With a steadfast commitment to scientific excellence and patient-centricity, Alivus Life Sciences Limited is poised to remain a leader in the pharmaceutical industry for years to come.
Company Details
Key Leadership
ALIVUS Share Price: Frequently Asked Questions
What is the current share price of Alivus Life Sciences Limited?
Alivus Life Sciences Limited (ALIVUS) trades at ₹1374.20 on NSE and BSE. Market cap ₹16.87K (Cr). Educational data only.
What is the P/E ratio of Alivus Life Sciences Limited?
Alivus Life Sciences Limited has a P/E of 27.98x vs industry average 34.89x.
What is the Bull Run score for Alivus Life Sciences Limited?
Alivus Life Sciences Limited has a Bull Run score of 58.6/100 based on 25+ financial parameters.
Does Alivus Life Sciences Limited pay dividends?
Alivus Life Sciences Limited has a dividend yield of 0.43%. Past dividends don't guarantee future payments.
What is the ROE of Alivus Life Sciences Limited?
Alivus Life Sciences Limited has ROE of 18.36%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Alivus Life Sciences Limited?
Alivus Life Sciences Limited has debt-to-equity of 0.00.
Is Alivus Life Sciences Limited a good investment?
Bull Run gives Alivus Life Sciences Limited a score of 58.6/100. This is not investment advice — consult a SEBI-registered advisor.